Financials
Financial year 2025
Eurotranspharma Belgium from Aalst, company number BE0541617712, closed financial year 2025 with a result of € 471,104 after tax. For that financial year Eurotranspharma Belgium recorded revenue of € 27 million and equity of € 784,198. Compared with financial year 2024, the result moved from € 28,815 to € 471,104. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.
€ 784,198
▲ 150% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 471,104
▲ € 442,289 vs 2024
Profit after tax over the fiscal year.
€ 1.3 million
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -1,352.
People and assets in 2025
131.8
▼ 4.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 9.1 million
▲ 2% vs 2024
€ 69,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 69,471
▼ 47% vs 2024
Of which on lease € 11,292.
Debts at end 2025
€ 3.7 million
▼ 23% vs 2024
€ 535,071 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 3.3 million
▼ 47% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 62 days on average.
€ 1.4 million
▲ 31% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 24,138,256 | € 26,317,811 | € 26,671,125 | € 27,039,656 | ▲ 1% |
| Profit after taxes | € 198,379 | € 56,522 | € 28,815 | € 471,104 | ▲ € 442,289 |
| Equity | € 227,757 | € 284,279 | € 313,094 | € 784,198 | ▲ 150% |
| Total debts | € 11,912,786 | € 10,155,609 | € 12,088,958 | € 8,406,239 | ▼ 30% |
| Cash | € 1,685,802 | € 758,852 | € 1,164,091 | € 1,334,231 | ▲ 15% |
| Land & buildings | € 20,936 | € 99,511 | € 110,296 | € 97,228 | ▼ 12% |
| Retained profit | € -557,793 | € -501,271 | € -472,456 | € -1,352 | ▲ € 471,104 |
| Bank debt | € 4,940,487 | € 4,800,131 | € 4,771,343 | € 3,682,100 | ▼ 23% |
| Balance sheet total | € 12,140,544 | € 10,439,888 | € 12,402,052 | € 9,190,436 | ▼ 26% |
| Employees (FTE) | 118.8 | 130.8 | 136.3 | 131.8 | ▼ 4.5 |
Key figures of Eurotranspharma Belgium, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Eurotranspharma Belgium?
What happened at Eurotranspharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 471,104 (▲ € 442,289 vs 2024). Source: NBB ↗
- Business Promotion and Management sprl stepped down as director. NBB
- New establishment in Aalst. KBO
- Business Promotion and Management sprl became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in La Louvière. KBO
In short
From € 198,379 profit in 2022 to € 471,104 profit in 2025.
Paid € 14,699 in corporate taxes since 2022.
Best year ever: 2025, with € 471,104 profit.
Pays suppliers within 62 days on average.
A new publication or filing at Eurotranspharma Belgium? We notify you, reason included.
Follow Eurotranspharma BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Movianto International BV.
Directors
According to the 2025 annual accounts
Business Promotion and Management sprl
Director · represented by Benoît Latteur
since 2018 · until 2026
Shareholders
Movianto International BV
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Waterkeringstraat 1
9320 Aalst
Chemin de la Reconversion(H-G) 91
7110 La Louvière
Active since 25 October 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0541.617.712
- VAT number
- BE 0541.617.712
- Registered office
- Waterkeringstraat 1, 9320 Aalst
- Names & denominations
- Eurotranspharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 November 2013
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Goederenvervoer over de weg
Andere vervoerondersteunende activiteiten
Opslag
Logistieke diensten